New pill aims to tame kidney disease in Long-Term trial
NCT ID NCT07616700
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new tablet called HSK39297 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The trial includes 73 adults who have already taken the drug in a previous study. They will take the tablet once daily for an extended period, with a possible dose increase if needed. The main goal is to check long-term safety and how well the drug controls protein in the urine, a key sign of kidney damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HSK39297 tablets
What this could lead to
If successful, this could point toward a new oral treatment option to control IgA nephropathy and reduce kidney damage over the long term.
What could go wrong
This is an early Phase 2 study with only 73 participants and no placebo group, so results may not confirm effectiveness. Long-term safety is still unknown, and the drug may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
COMPLETEDBeijing, China
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••